NCT01853306View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

March 18, 2013

Primary Completion Date

May 3, 2017

Study Completion Date

June 29, 2017

Conditions
OncologyBRCA MutatedHigh Grade Serous Ovarian CancerBRCA Mutated Breast Cancer
Interventions
DRUG

Veliparib

veliparib

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY